The effect of low molecular weight heparin on prognosis of patients with radical gastrectomy

The effect of low molecular weight heparin on prognosis of patients with radical gastrectomy | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The effect of low molecular weight heparin on prognosis of patients with radical gastrectomy Yanqiang Wei, Wenxing Li, Jinhe Lin, Danfang Wang, Chengxue Dang, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4550116/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The safety and feasibility of perioperative anticoagulation remains unclear and controversial. In this study, we aim to explored whether postoperative anticoagulation with low molecular weight heparin (LMWH) can improve long-term survival in patients undergoing radical gastrectomy. We retrospectively enrolled 1486 patients diagnosed with primary gastric cancer (GC) and undergoing radical resection in our medical center between January 2015 and February 2018. Patients were grouped into anticoagulation group and non-anticoagulation group based on postoperative anticoagulant therapy, and clinicopathological features were collected and compared. The correlation between parameters and survival was assessed using the Kaplan-Meier method and univariate and multivariate COX regression models. Forest plots were constructed based on subgroup analysis and multivariate Cox regression analysis. Among the 1486 patients, 513 (34.5%) received postoperative anticoagulation therapy. In multivariate survival analysis, non-anticoagulation significantly reduced overall survival (OS), but not disease-free survival (DFS). Furthermore, elevated plasma CEA, CA19-9, lower erythrocyte and lymphocyte counts, and advanced N stage were also shown to be independent poor prognostic factors for OS, and they were also independent prognostic factors for DFS, in addition to lymphocyte counts. Anticoagulation with LMWH after radical gastrectomy can significantly improve the OS of GC patients. Health sciences/Gastroenterology/Gastrointestinal diseases/Stomach diseases/Gastric cancer Health sciences/Oncology/Surgical oncology Gastric cancer Overall survival Postoperative anticoagulation Prognostic factor Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Introduction GC remains a major killer worldwide, ranking fifth in incidence and fourth in mortality among malignancies [ 1 ] . Radical resection is still the best treatment option for GC under the premise of surgical indications [ 2 ] . However, despite significant improvements in surgical technique and perioperative management, the incidence of complications after radical gastrectomy remains high, with an estimated incidence of 12.8–14% [ 3 , 4 ] . venous thromboembolism (VTE) is a common complication in patients with cancer. The incidence of first-time VTE in patients with active cancer was 5.8 per 100 person-years. The overall recurrence rate was 9.6 per 100 person-years, with a maximum of 22.1 per 100 person-years in the first 6 months [ 5 ] . GC and surgical treatment are both risk factors for VTE and significantly increase mortality. Studies have shown that the incidence of VTE in GC patients after surgery is about 2%, accounting for about 50% of the early postoperative mortality [ 6 – 8 ] . Many studies have reported the efficacy of perioperative anticoagulant or antiplatelet drugs in the prevention or treatment of VTE. Although the benefits of LMWH for cancer patient survival are controversial, it appears to be associated with a reduction in VTE, whereas the increase in bleeding is slight and manageable. Recent studies have shown that heparin has anti-cancer effects in addition to its protective effect on the incidence of VTE, such as inhibition of tumor angiogenesis and distant metastases [ 9 – 11 ] . However, whether anticoagulant drugs affect the long-term prognosis of patients with GC is unclear [ 12 ] . In this study, we aimed to investigate whether anticoagulation after radical gastrectomy improves the long-term outcomes of patients. Results Associations between anticoagulation status and clinicopathological factors Among the 1486 patients, 513 (34.52%) received postoperative anticoagulation therapy. No postoperative major bleeding occurred in all patients (data not shown). In the anticoagulation group, prothrombin time (PT) (13 vs 12.9 seconds) and thrombin time (TT) (16.3 vs 16.1 seconds) were higher while albumin (38.1 vs 38.3 g/L), D-dimer (0.4 vs 0.6 mg/L) and fibrin degradation products (FDP) (0.9 vs 1.3 mg/L) were lower. There were no significant differences in age, sex, tumor markers, activated partial prothrombin time (APTT), degree of differentiation, TNM stage and blood routine examination. Most importantly, OS (28 vs 21 months) and DFS (28 vs 20 months) were significantly higher in the anticoagulation group than in the non-anticoagulation group (Table 1 ). Table 1 Demographic and baseline characteristics of patients. Characteristics Overall (N = 1486) Control (N = 973) Anticoagulation (N = 513) P value Gender 0.931 Male 1123(75.6) 736(75.6) 387(75.4) Female 363(24.4) 237(24.4) 126(24.6) Age, year 61(54–67) 61(53–67 62(57–69) 0.235 Albumin, g/L 38.5(35.5–41.4) 38.3(35.2–41.2) 38.1(35.38–39.83) 0.034 Globulin, g/L 25.2(22.7–28) 25(22.58–27.9) 26.79(23.73–28.68) 0.167 PT, second 13(12.4–13.5) 12.9(12.3–13.5) 13(12.3–13.6) < 0.001 APTT, second 34.55(32-37.3) 34.4(32-37.2) 36(33-37.7) 0.238 TT, second 16.2(15.6–16.8) 16.1(15.5–16.7) 16.3(15.7–17.2) < 0.001 Fibrinogen, g/L 3.3(2.7–3.97) 3.3(2.71-4) 3.63(2.97–4.5) 0.196 D-dimer, mg/L 0.6(0.2–1.1) 0.6(0.2–1.2) 0.4(0.2–0.9) 0.009 FDP, mg/L 1.2(0.7–2.3) 1.3(0.7–2.6) 0.9(0.5–1.4) 0.01 CEA, ng/ml 2.36(1.38–4.47) 2.44(1.38–4.92) 2.55(1.45–8.26) 0.33 CA19-9, U/ml 10.79(6.37–21.39) 10.75(6.19–22.07) 11.45(5.75–18.14) 0.772 CA72-4, U/ml 2.04(1.17–5.42) 2.05(1.17–5.88) 1.89(1.44–3.65) 0.42 OS, month 24(13–46) 21(13–43) 28(12–69) < 0.001 DFS, month 24(13–45) 20(12–43) 28(12–69) < 0.001 Differentiation # 0.96 Yes 456(30.7) 299(30.7) 157(30.6) No 1030(69.3) 674(69.3) 356(69.4) T stage < 0.001 1 216(14.5) 121(12.4) 95(18.5) 2 119(8) 80(8.2) 39(7.6) 3 301(20.3) 237(24.4) 64(12.5) 4 850(57.2) 535(55) 315(61.4) N stage 0.027 0 594(40) 375(38.5) 219(42.7) 1 282(19) 206(21.2) 76(14.8) 2 248(16.7) 162(16.6) 86(16.8) 3 362(24.4) 230(23.6) 132(25.7) TNM stage 0.053 1 284(19.1) 169(17.4) 115(22.4) 2 229(15.4) 157(16.1) 72(14) 3 973(65.5) 647(66.5) 326(63.5) Tumor size, cm 4(2.5-6) 4(2.5-6) 5(3–8) Erythrocyte 4.26(3.79–4.64) 4.25(3.75–4.64) 4.06(3.7–4.49) 0.393 Hemoglobin, g/L 128(108–142) 127(106.25–142) 123(97-140.5) 0.176 Platelet 201(155-253.5) 200(153–248) 230(161–277) 0.129 Leukocyte 5.35(4.32–6.74) 5.28(4.33–6.79) 5.48(4.28–6.63) 0.898 Neutrophil 3.13(2.39–4.21) 3.11(2.38–4.25) 3.13(2.19–4.23) 0.999 Lymphocyte 1.53(1.18–1.93) 1.53(1.17–1.94) 1.49(1.16–1.92) 0.691 Monocyte 0.39(0.27–0.5) 0.4(0.28–0.52) 0.46(0.36–0.56) 0.081 Abbreviation: PT prothrombin time, APTT activated partial prothrombin time, TT thrombin time, FDP fibrin degradation products, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19 − 9, CA72-4 carbohydrate antigen 72 − 4, OS overall survival, DFS disease free survival, TNM tumor node metastasis. # Poorly differentiated and undifferentiated were defined as no differentiation, and moderately differentiated and well-differentiated are defined as differentiation. Results of survival analysis Continuous variables were divided into two groups according to their respective suitable cut-off values (Supplementary Fig. 1 and Supplementary Fig. 2). In univariable analysis, age, anticoagulation status, albumin, globulin, PT, TT, fibrinogen, D-dimer, FDP, CEA, CA19-9, CA72-4, T stage, N stage, TNM stage, tumor size, erythrocyte, hemoglobin, platelet, leukocyte, neutrophil, lymphocyte and monocyte were associated with OS of GC. In multivariable analysis, non-anticoagulation (hazard ratio [HR], 1.397; 95% CI, 1.018–1.918; P = 0.038), higher CEA (HR, 1.792; 95% CI, 1.259–2.549; P = 0.001), higher CA19-9 (HR, 1.719; 95% CI, 1.19–2.483; P = 0.004), advanced N stage (N1: HR, 1.809; 95% CI, 0.988–3.313; P = 0.055; N2: HR, 2.521; 95% CI, 1.375–4.621; P = 0.003; N3: HR, 4.627; 95% CI, 2.63–8.141; P < 0.001), lower erythrocyte (HR, 1.666; 95% CI, 1.16–2.394; P = 0.006) and lower lymphocyte (HR, 1.684; 95% CI, 1.111–2.553; P = 0.014) were independent significant risk factors for OS in GC (Table 2 , Fig. 1 ). In univariate analysis of DFS for GC, the relevant factors were the same as those of OS except for monocytes. In multivariate analysis, however, only higher CEA (HR, 1.861; 95% CI, 1.333–2.579; P < 0.001), CA19-9 (HR, 1.53; 95% CI, 1.066–2.196; P = 0.021), advanced N stage (N1: HR, 1.81; 95% CI, 1.039–3.153; P = 0.036; N2: HR, 2.519; 95% CI, 1.439–4.413; P = 0.001; N3: HR, 4.301; 95% CI, 2.545–7.269; P < 0.001), and lower erythrocyte (HR, 1.681; 95% CI, 1.191–2.372; P = 0.003) were identified as independent risk factors for DFS (Table 3 , Fig. 2 ). Table 2 Univariate and multivariate COX regression analyses for overall survival of GC patients. Parameters Group 1 Univariate analysis Multivariate analysis HR 95%CI P value HR 95%CI P value Gender Female vs male 1.087 0.909–1.301 0.36 Age < 65 vs ≥ 65 1.489 1.272–1.742 < 0.001 1.273 0.915–1.771 0.151 Anticoagulant Yes vs no 1.551 1.312–1.833 < 0.001 1.397 1.018–1.918 0.038 Albumin ≥ 32.6 vs < 32.6 2.541 1.987–3.25 < 0.001 1.58 0.987–2.531 0.057 Globulin < 26.3 vs ≥ 26.3 1.243 1.028–1.503 0.025 1.33 0.963–1.837 0.083 PT < 13.2 vs ≥ 13.2 1.3 1.114–1.516 0.001 1.148 0.833–1.58 0.399 APTT < 37.8 vs ≥ 37.8 1.155 0.964–1.384 0.118 TT ≥ 16.5 vs < 16.5 1.361 1.141–1.623 0.001 0.977 0.655–1.458 0.909 Fibrinogen < 3.7 vs ≥ 3.7 1.751 1.5-2.043 < 0.001 1.003 0.722–1.394 0.985 D-dimer < 1.2 vs ≥ 1.2 2.494 2.111–2.947 < 0.001 1.276 0.732–2.222 0.39 FDP < 3 vs ≥ 3 2.548 2.139–3.034 < 0.001 1.416 0.806–2.488 0.226 CEA < 6.1 vs ≥ 6.1 2.477 2-3.068 < 0.001 1.792 1.259–2.549 0.001 CA19-9 < 35.1 vs ≥ 35.1 2.487 1.939–3.19 < 0.001 1.719 1.19–2.483 0.004 CA72-4 < 2.9 vs ≥ 2.9 1.981 1.595–2.461 < 0.001 1.142 0.826–1.58 0.422 Differentiation Yes vs no 0.876 0.74–1.036 0.122 T stage 1 Ref Ref 2 1.833 1.143–2.94 0.012 1.981 0.684–5.743 0.208 3 4.009 2.768–5.805 < 0.001 3.512 0.936–13.173 0.063 4 4.51 3.21–6.335 < 0.001 3.223 0.889–11.685 0.075 N stage 0 Ref Ref 1 2.35 1.863–2.966 < 0.001 1.809 0.988–3.313 0.055 2 2.826 2.238–3.568 < 0.001 2.521 1.375–4.621 0.003 3 4.115 3.352–5.052 < 0.001 4.627 2.63–8.141 < 0.001 TNM stage 1 Ref Ref 2 2.565 1.748–3.764 < 0.001 0.715 0.203–2.516 0.602 3 5.797 4.217–7.97 < 0.001 0.787 0.204–3.029 0.727 Tumor size 1.157 1.124–1.191 < 0.001 1.026 0.965–1.09 0.412 Erythrocyte ≥ 4.5 vs < 4.5 1.837 1.478–2.282 < 0.001 1.666 1.16–2.394 0.006 Hemoglobin ≥ 105 vs < 105 1.7 1.379–2.095 < 0.001 1.004 0.701–1.438 0.982 Platelet ≥ 136 vs < 136 1.29 1.051–1.583 0.015 1.5 0.957–2.352 0.077 Leukocyte < 8.2 vs ≥ 8.2 1.632 1.233–2.162 0.001 1.594 0.809–3.14 0.178 Neutrophil < 5.7 vs ≥ 5.7 1.749 1.329–2.303 < 0.001 0.692 0.33–1.449 0.329 Lymphocyte ≥ 1.1 vs < 1.1 1.973 1.588–2.452 < 0.001 1.684 1.111–2.553 0.014 Monocyte < 0.4 vs ≥ 0.4 1.268 1.05–1.533 0.014 1.35 0.967–1.886 0.078 1 The left group served as the control group. Abbreviation: HR hazard ratio, CI confidence interval, Ref reference, PT prothrombin time, APTT activated partial prothrombin time, TT thrombin time, FDP fibrin degradation products, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, CA72-4 carbohydrate antigen 72-4, TNM tumor node metastasis. Table 3 Univariate and multivariate COX regression analyses for disease-free survival of GC patients. Parameters Group 1 Univariate analysis Multivariate analysis HR 95%CI P value HR 95%CI P value Gender Female vs male 1.067 0.895–1.273 0.467 Age < 65 vs ≥ 65 1.418 1.213–1.657 < 0.001 1.322 0.962–1.816 0.086 Anticoagulant Yes vs no 1.423 1.21–1.673 < 0.001 1.305 0.963–1.768 0.086 Albumin ≥ 32.6 vs < 32.6 2.29 1.786–2.937 < 0.001 1.263 0.784–2.036 0.338 Globulin < 26.3 vs ≥ 26.3 1.209 1.004–1.456 0.045 1.240 0.908–1.692 0.176 PT < 13.2 vs ≥ 13.2 1.239 1.064–1.442 0.006 1.129 0.935–1.528 0.430 APTT < 37.8 vs ≥ 37.8 1.048 0.873–1.258 0.615 TT ≥ 16.5 vs < 16.5 1.325 1.111–1.58 0.002 0.956 0.649–1.409 0.820 Fibrinogen < 3.7 vs ≥ 3.7 1.668 1.431–1.943 < 0.001 1.034 0.753–1.42 0.836 D-dimer < 1.2 vs ≥ 1.2 2.27 1.918–2.687 < 0.001 1.217 0.702–2.109 0.485 FDP < 3 vs ≥ 3 2.23 1.864–2.667 < 0.001 1.284 0.735–2.243 0.380 CEA < 6.1 vs ≥ 6.1 2.352 1.902–2.908 < 0.001 1.861 1.333–2.579 < 0.001 CA19-9 < 35.1 vs ≥ 35.1 2.276 1.778–2.914 < 0.001 1.530 1.066–2.196 0.021 CA72-4 < 2.9 vs ≥ 2.9 1.932 1.566–2.383 < 0.001 1.211 0.888–1.65 0.226 Differentiation Yes vs no 0.874 0.741–1.032 0.113 T stage 1 Ref 2 1.819 1.166–2.837 0.008 1.364 0.486–3.83 0.555 3 3.612 2.54–5.137 < 0.001 2.064 0.609–6.993 0.244 4 4.148 3.013–5.712 < 0.001 2.101 0.638–6.92 0.222 N stage 0 Ref 1 2.239 1.783–2.813 < 0.001 1.810 1.039–3.153 0.036 2 2.794 2.226–3.507 < 0.001 2.519 1.439–4.413 0.001 3 4.095 3.352–5.004 < 0.001 4.301 2.545–7.269 < 0.001 TNM stage 1 Ref 2 2.367 1.657–3.381 < 0.001 1.024 0.319–3.284 0.968 3 5.043 3.762–6.761 < 0.001 1.136 0.318–4.062 0.845 Tumor size 1.158 1.126–1.191 < 0.001 1.032 0.975–1.093 0.279 Erythrocyte ≥ 4.5 vs < 4.5 1.773 1.436–2.189 < 0.001 1.681 1.191–2.372 0.003 Hemoglobin ≥ 105 vs < 105 1.602 1.302–1.972 < 0.001 0.969 0.682–1.376 0.860 Platelet ≥ 136 vs < 136 1.251 1.019–1.536 0.032 1.516 0.993–2.314 0.054 Leukocyte < 8.2 vs ≥ 8.2 1.592 1.205–2.102 0.001 1.350 0.686–2.655 0.384 Neutrophil < 5.7 vs ≥ 5.7 1.73 1.318–2.271 < 0.001 0.849 0.413–1.742 0.655 Lymphocyte ≥ 1.1 vs < 1.1 1.82 1.465–2.261 < 0.001 1.387 0.929–2.071 0.110 Monocyte < 0.4 vs ≥ 0.4 1.172 0.974–1.41 0.093 1 The left group served as the control group. Abbreviation: HR hazard ratio, CI confidence interval, Ref reference, PT prothrombin time, APTT activated partial prothrombin time, TT thrombin time, FDP fibrin degradation products, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19 − 9, CA72-4 carbohydrate antigen 72 − 4, TNM tumor node metastasis. To explore the prognostic value of anticoagulation in different subgroups, we performed subgroup analyses. Kaplan-Meier curves showed that postoperative anticoagulation was associated with OS regardless of D-dimer level, whereas in the high D-dimer group it was not associated with DFS (Fig. 3 ). Univariate analysis of OS showed that in the subgroup of female (HR: 2.031 vs 1.431), age < 65 years (HR: 1.607 vs 1.501), earlier T (T1 vs T2 vs T3, HR: 3.046 vs 1.93 vs 1.532) and TNM stages (stage I vs stage II vs stage III, HR: 3.305 vs 2.047 vs 1.389), and lower platelet counts (HR: 2.119 vs 1.482), the non-anticoagulant group showed higher HR. Anticoagulation was associated with OS regardless of TNM stage, D-dimer level, FDP level and platelet level (Fig. 4 ). Although postoperative anticoagulation was not an independent risk factor for DFS, we also performed subgroup analyses (Fig. 5 ). Discussion In our current study, we explored the relationship between postoperative anticoagulation and long-term survival in patients undergoing radical gastrectomy for GC. Our results shows that postoperative anticoagulation can significantly improve OS in patients with GC, but there is no significant correlation with DFS. This enlightens us that routine anticoagulation after gastrectomy is necessary. Through multivariate survival analysis of anticoagulation status, tumor markers, blood routine, coagulation indexes, and pathological features, we confirmed that anticoagulation can significantly improve OS in patients after radical gastrectomy. Coagulation activation is strongly associated with tumor progression. The improvement of prognosis may be related to the influence of anticoagulant drugs on tumor progression. Pathological activation of the coagulation system occurs in almost all forms of cancer, particularly epithelial malignancies. There is a bidirectional interaction between coagulation activity and cancer, and the activation of the cancer-associated pathological hemostatic system promotes the progression of malignant tumors [ 13 ] . This was supported by studies showing that men with hemophilia have a lower incidence of prostate cancer [ 14 ] . Tissue factors may affect angiogenesis and the pretumorigenic inflammatory environment, thereby supporting tumor development [ 15 ] . Microthrombi in the blood protect circulating tumor cells from attack by immune cells [ 16 ] . In fact, cancer cells can activate the hemostatic system through the release of tissue factors, the expression of procoagulant proteins, the exposure of procoagulant lipids, the release of inflammatory cytokines and microparticles, and the adhesion to host vascular cells [ 17 , 18 ] . Moreover, LMWH downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB [ 19 ] . This evidence is consistent with our findings. By comparing baseline data, we found that DFS in the anticoagulant group was significantly higher than that in the non-anticoagulant group (median: 28 vs 20 months). Although anticoagulation was not significantly associated with DFS in the multivariate survival analysis, this may be related to our relatively small sample size. Although many studies have reported a close correlation between tumor hypercoagulability and tumor progression, the improvement of OS by postoperative anticoagulant therapy may be related to its effect on cancer-associated thrombosis. Cancer-associated thrombosis, including arterial thrombosis and VTE, significantly affects the quality of life and shortens survival. Although risk assessment tools have been shown to be effective in identifying patients at risk for VTE (including Padua prediction score, Caprini risk assessment model, IMPROVE models, the Geneva risk score and the Kucher score) [ 20 – 22 ] , and there have been advances in perioperative management and prophylaxis measures, the risk of VTE has increased in recent years. The risk of VTE is related to the type of cancer GC is one of the cancers with the highest risk of VTE as well as individual patient differences and new anticancer therapies including antiangiogenic drugs, multi-targeted tyrosine kinase inhibitors, immunomodulatory drug combinations [ 8 , 23 , 24 ] . 1-year cumulative risk of pulmonary embolism and deep vein thrombosis for gastroesophageal cancer was 2.3% and 2.19%, respectively. The etiology-specific risk of pulmonary embolism and deep vein thrombosis increased by 10–30 times in patients undergoing surgery for gastroesophageal cancer, and the post-operative HR gradually decreases until it levels off, but remains higher than that in the general population [ 8 ] . Therefore, the earlier the use of anticoagulant therapy after surgery, the more effective the prevention of VTE. A large clinical study reported that GC resection exhibited the highest rates of VTE (4.1%). The diagnosis of VTE was associated with increased mortality (10.2% vs 1.7%) and prolonged hospital stay (19.5 days vs 7.5 days), as well as increased rates of readmission and admission costs [ 24 ] . Therefore, early use of anticoagulant drugs after surgery can effectively reduce VTE events and thus reduce mortality. According to ASCO VTE guideline, patients who are candidates for extended pharmacologic thromboprophylaxis after surgery may be offered prophylactic doses of LMWH (Strength of recommendation: Strong) [ 25 ] . This may explain our finding that postoperative anticoagulation prolongs OS in patients with GC. Non-anticoagulation was an independent risk factor for the long-term prognosis of GC (HR: 1.397, 95% CI: 1.018–1.918). In addition to the anticoagulant mechanism, heparin also exerts anticancer properties through a non-anticoagulant mechanism [ 26 ] . Heparin can affect cancer cell proliferation, adhesion, angiogenesis, migration, and invasion through a variety of mechanisms, including inhibition of heparinase, P-/L-selectin, angiogenesis, and interference with the CXCL12-CXCR4 axis [ 12 , 27 ] . Heparin directly induces apoptosis in cancer cells through cell cycle arrest, as well as enhances tumor cell sensitivity to chemotherapy by increasing drug uptake and reversing the downregulation of tumor suppressor genes [ 28 , 29 ] . Nevertheless, the evidence for the potential survival effect of LMWH is controversial [ 12 ] . Moreover, few studies have reported the relationship between LMWH and the prognosis of GC. Our study provides evidence that postoperative anticoagulation prolongs OS in GC. It is important to note that perioperative anticoagulation may increase the risk of bleeding. One study showed that patients with esophageal cancer who were treated with anticoagulation in the perioperative period had 22.2% postoperative bleeding incidence, compared with 5.8% in the non-anticoagulation group [ 30 ] . A clinical study of 1536 patients found that delayed massive hemorrhage after gastrectomy accounted for 0.9%, of which 3 cases died, and early postoperative hemorrhage accounted for 1.2%, and no death cases [ 31 ] . A recent study found that preoperative and postoperative use of antithrombotic drugs did not increase bleeding complications after radical gastrectomy [ 32 ] . Similarly, another study reported that preoperative use of antiplatelet and/or anticoagulants does not significantly increase the risk of major bleeding after laparoscopic GC surgery [ 33 ] . In our current study, no postoperative major bleeding occurred in the anticoagulant and non-anticoagulant groups, we can conclude that perioperative use of anticoagulant drugs is relatively safe based on the above evidence. The use of anticoagulants needs to meet clinical indications. Individualized treatment with LMWH or oral anticoagulants combined with bleeding risk and VTE risk assessment is critical. This study has some limitations in that we did not monitor new postoperative VTE events and the effect of postoperative anticoagulation on VTE risk. The incidence of postoperative major bleeding is relatively low, and a larger sample size may be needed to explore the effect of postoperative anticoagulant drugs on the postoperative bleeding rate. In our study we did not investigate the survival difference between prolonged perioperative anticoagulation and postoperative anticoagulation alone. One study reported that prolonged perioperative anticoagulation did not improve DFS or OS in patients with colorectal cancer undergoing surgical resection compared with in-hospital postoperative thromboprophylaxis [ 34 ] . The optimal timing of anticoagulation therapy in patients with GC needs to be further explored. Conclusions Based on previous evidence and our findings, we believe that routine anticoagulation with LMWH after radical gastrectomy can improve prognosis without increasing the risk of postoperative bleeding. Materials and Methods Patients A total of 1486 GC patients admitted to the The First Affiliated Hospital of Xi'an Jiaotong University between January 2015 and February 2018 were retrospectively enrolled in this study. All patients met the following inclusion criteria: (1) diagnosed with GC for the first time and underwent radical gastrectomy, (2) aged 18+, (3) All patients were assessed for bleeding risk and were at low risk. Exclusion criteria refer to (1) lack of pretreatment coagulation markers, (2) loss to follow-up. Follow-up was conducted by telephone or outpatient clinic. We collected data including age, sex, histological differentiation, tumor markers, coagulation markers, tumor-node-metastasis (TNM) stage and complete blood count from patients before receiving any treatment. Overall survival (OS) was defined as the time interval between the date of first diagnosis and the date of death from any cause or the date of last follow-up. Disease-free survival (DFS) is defined as the time from first diagnosis to postoperative tumor recurrence or metastasis or loss to follow-up. This study was approved by the Ethics Committee of First Affiliated Hospital of Xi’an Jiaotong University. Informed consent was obtained from all subjects and/or their legal guardian(s). All methods were performed in accordance with the relevant guidelines and regulations. Statistical analyses Postoperative anticoagulation is defined as the use of LMWH for at least one day (such as low molecular weight heparin calcium injection, enoxaparin sodium, or Nagchu heparin calcium). Patients were divided into two groups according to their anticoagulation status and clinicopathological features were compared. Before performing survival analysis, appropriate cut-off values for continuous variables were obtained through X-tile software (version 3.6.1). The count data was expressed as counts and the frequencies in parentheses and compared by the Chi-square and Fisher's exact tests . Whether the continuous variable follows a normal distribution is tested by the Kolmogorov-Smirnov one-sample test . Normal distribution continuous variables were compared by student’s t-test , while nonnormal distribution continuous variables were represented as median and interquartile range in parentheses and compared by Mann-Whitney U test . The independent prognostic factors for OS and DFS of GC were determined by Kaplan-Meier curves, univariate and multivariate COX regression analysis. Continuous variables and categorical variables with P < 0.05 in univariate analysis were included in multivariate survival analysis. Subgroup analysis was performed according to age, sex, T stage, N stage, TNM stage, D-dimer level, FDP level and platelet level to evaluate the prognostic value of postoperative anticoagulation. The results of multivariate survival analysis and subgroup analysis were presented by forest plot. Statistical analysis was performed by SPSS software (version 25.0). P < 0.05 (two-tailed) was considered to be statistically significant. Declarations Competing Interests The authors have no relevant financial or non-financial interests to disclose. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Author Contribution Conceived and designed the experiments: YQW, CXD, DMD, XZ. Performed the experiments: XZ, WXL, JHL. Analyzed the data: XZ, DFW. Contributed reagents/ materials/ analysis tools: XZ, WXL, DFW. Wrote the manuscript: YQW, XZ. All authors reviewed and approved the final manuscript. Acknowledgements Not applicable. Data Availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. References Sung, H. et al . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians. 71, 209–249 (2021). In, H. et al . Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database[J]. Annals of Surgical Oncology. 24, 3683–3691 (2017). Wang, S. et al . Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies[J]. World Journal of Surgical Oncology. 17, (2019). Luo, B. et al . The ratio of serum C-reactive protein level on postoperative day 3 to day 2 is a good marker to predict postoperative complications after laparoscopic radical gastrectomy for gastric cancer[J]. Langenbecks Arch Surg. 407, 1451–1460 (2022). Cohen, A.T., Katholing, A., Rietbrock, S., Bamber, L. and Martinez, C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study[J]. Thromb Haemost. 117, 57–65 (2017). Kakkar, A., Haas, S., Wolf, H. and Encke, A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy[J]. Thrombosis and haemostasis. 94, 867–871 (2005). Agnelli, G. et al . A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery[J]. Annals of Surgery. 243, 89–95 (2006). Björklund, J. et al . Risk of Venous Thromboembolic Events After Surgery for Cancer[J]. JAMA network open. 7, e2354352 (2024). Giannas, E. and Kontovounisios, C. The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature[J]. Journal of Clinical Medicine. 12, 7173 (2023). Kuderer, N.M., Ortel, T.L. and Francis, C.W. Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival[J]. Journal of Clinical Oncology. 27, 4902–4911 (2009). Wei, F. et al . Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates[J]. Clinical cancer research: an official journal of the American Association for Cancer Research. 29, 2525–2539 (2023). Zhang, N. et al . Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms[J]. J Cancer Res Clin Oncol. 142, 1807–1816 (2016). Sharma, B.K., Flick, M.J. and Palumbo, J.S. Cancer-Associated Thrombosis: A Two-Way Street[J]. Seminars in Thrombosis and Hemostasis. 45, 559–568 (2019). Dunn, A.L., Austin, H. and Soucie, J.M. Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System[J]. Haemophilia. 18, 532–539 (2012). Milsom, C.C. et al . Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis[J]. Cancer Res. 68, 10068–10076 (2008). Palumbo, J.S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination[J]. Semin Thromb Hemost. 34, 154–160 (2008). Falanga, A., Panova-Noeva, M. and Russo, L. Procoagulant mechanisms in tumour cells[J]. Best Pract Res Clin Haematol. 22, 49–60 (2009). Donnellan, E., Kevane, B., Bird, B.R. and Ainle, F.N. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management[J]. Curr Oncol. 21, 134–143 (2014). Ettelaie, C. et al . Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-kappaB[J]. Biochim Biophys Acta. 1812, 1591–1600 (2011). Ding, Y. et al . Risk assessment for postoperative venous thromboembolism using the modified Caprini risk assessment model in lung cancer[J]. Journal of Thoracic Disease. 15, 3386–3396 (2023). Zhang, W., Sun, R., Hu, X., Chen, Z. and Lai, C. Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer[J]. World J Surg Oncol. 21, 299 (2023). Ding, Y. et al . Risk assessment for postoperative venous thromboembolism using the modified Caprini risk assessment model in lung cancer[J]. J Thorac Dis. 15, 3386–3396 (2023). Bar, J. et al . Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study[J]. European journal of cancer (Oxford, England : 1990). 120, 122–131 (2019). Pan, C.S. et al . Venous thromboembolism in cancer surgery: A report from the nationwide readmissions database[J]. Surgery Open Science. 9, 58–63 (2022). Key, N.S. et al . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update[J]. J Clin Oncol. 41, 3063–3071 (2023). Beurskens, D.M.H. et al . The Anticoagulant and Nonanticoagulant Properties of Heparin[J]. Thromb Haemost. 120, 1371–1383 (2020). Ma, S.N. et al . The anti-cancer properties of heparin and its derivatives: a review and prospect[J]. Cell Adh Migr. 14, 118–128 (2020). Chen, X., Xiao, W., Qu, X. and Zhou, S. The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro[J]. Cancer Invest. 26, 718–724 (2008). Pan, Y. et al . Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation[J]. Mol Pharmacol. 87, 378–390 (2015). Aoyama, T. et al . Postoperative Bleeding After Esophagectomy for Esophageal Cancer in Patients Receiving Antiplatelet and Anticoagulation Treatment[J]. Anticancer Research. 40, 2359–2364 (2020). Song, W. et al . The delayed massive hemorrhage after gastrectomy in patients with gastric cancer: Characteristics, management opinions and risk factors[J]. European Journal of Surgical Oncology (EJSO). 40, 1299–1306 (2014). Matsui, R. et al . Relationship between antithrombotic drugs and postoperative outcomes in patients with gastric cancer after gastrectomy: a propensity matching analysis[J]. Gastric Cancer. 26, 833–842 (2023). Im, C. et al . Postoperative major bleeding risk in patients using oral antiplatelets and/or anticoagulants after laparoscopic gastric cancer surgery[J]. Annals of Surgical Treatment and Research. 104, 80 (2023). Auer, R.C. et al . Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial[J]. BMJ. 378, e071375 (2022). Additional Declarations No competing interests reported. Supplementary Files Additionalfile1.pdf Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4550116","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":318303031,"identity":"f37c90cb-2961-4f10-a99f-57f5c611c2b2","order_by":0,"name":"Yanqiang Wei","email":"","orcid":"","institution":"The First Affiliated Hospital of Xi'an Jiaotong University","correspondingAuthor":false,"prefix":"","firstName":"Yanqiang","middleName":"","lastName":"Wei","suffix":""},{"id":318303032,"identity":"db05c1c6-db1a-4bd3-90ba-0e254108b655","order_by":1,"name":"Wenxing Li","email":"","orcid":"","institution":"The First Affiliated Hospital of Xi'an Jiaotong University","correspondingAuthor":false,"prefix":"","firstName":"Wenxing","middleName":"","lastName":"Li","suffix":""},{"id":318303033,"identity":"39c82057-cb18-4098-934e-13c1ae148bb6","order_by":2,"name":"Jinhe Lin","email":"","orcid":"","institution":"First Affiliated Hospital of Xi’an Jiaotong University","correspondingAuthor":false,"prefix":"","firstName":"Jinhe","middleName":"","lastName":"Lin","suffix":""},{"id":318303036,"identity":"8a1cfcf1-0e6a-4c33-bffa-141a50df7ece","order_by":3,"name":"Danfang Wang","email":"","orcid":"","institution":"The First Affiliated Hospital of Xi'an Jiaotong University","correspondingAuthor":false,"prefix":"","firstName":"Danfang","middleName":"","lastName":"Wang","suffix":""},{"id":318303039,"identity":"d33e20fc-03eb-4a74-a800-698eb3ee4ac5","order_by":4,"name":"Chengxue Dang","email":"","orcid":"","institution":"The First Affiliated Hospital of Xi'an Jiaotong University","correspondingAuthor":false,"prefix":"","firstName":"Chengxue","middleName":"","lastName":"Dang","suffix":""},{"id":318303041,"identity":"4fd545aa-e993-4bd5-9375-886e21dd2bf5","order_by":5,"name":"Dongmei Diao","email":"","orcid":"","institution":"The First Affiliated Hospital of Xi'an Jiaotong University","correspondingAuthor":false,"prefix":"","firstName":"Dongmei","middleName":"","lastName":"Diao","suffix":""},{"id":318303046,"identity":"6c948851-0e48-433c-a8de-042516ad948c","order_by":6,"name":"Xin Zhang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABC0lEQVRIiWNgGAWjYDACCRgpwXwARPEbwAUJa2FLYJBIYJDcQKQWEIMHaD4xWuRnNz97+LXNIk9+ds83CcsfhyXMGZgP3uZhsMvDpYVxzjFzY5kzEsWMc85uNpBIOCxh2cCWbM3DkFyMSwuzRIKZtESFRGKzRO7GB0AtdQYHeMykeRgOJDbg0MImkf5NWsJAIrFNIufBAZAtBgf4v+HVwiORYyb5AWhLj0QO4wOIFh42vFokJHLKpBnOSCTOkEgzNpBIS5cwOMxmbDnHIBmnFvkZ6dskf7bVJc6fkfxMWsLGWsLgePPDG28q7HBqAQcBDzwswCSIMMCjHggYf8AYH/ArHAWjYBSMghEKAHNBTki0/XfeAAAAAElFTkSuQmCC","orcid":"","institution":"The First Affiliated Hospital of Xi'an Jiaotong University","correspondingAuthor":true,"prefix":"","firstName":"Xin","middleName":"","lastName":"Zhang","suffix":""}],"badges":[],"createdAt":"2024-06-08 10:23:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4550116/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4550116/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":59524273,"identity":"5e153f74-da7c-4b0c-a339-dbdbf133c783","added_by":"auto","created_at":"2024-07-02 20:44:46","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":133846,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot showing results of multivariate survival analyses comparing association with overall survival.\u003c/p\u003e","description":"","filename":"Fig11.png","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/d66094c0ee59f06740c3e6cb.png"},{"id":59524274,"identity":"d5b52aaa-90e5-4600-8730-0ae394c72971","added_by":"auto","created_at":"2024-07-02 20:44:46","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":134388,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot showing results of multivariate survival analyses comparing association with disease-free survival.\u003c/p\u003e","description":"","filename":"Fig23.png","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/d5d967174c8cbcbd03e2b0d3.png"},{"id":59524279,"identity":"ee7ef94d-ee3c-4e71-b3dd-ceaa97734493","added_by":"auto","created_at":"2024-07-02 20:44:46","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":1135569,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan-Meier survival curves\u003c/p\u003e\n\u003cp\u003e(a) Kaplan-Meier survival curves of anticoagulation status for overall survival (OS); (b) Kaplan-Meier survival curves of anticoagulation status for disease-free survival (DFS); (c) Kaplan-Meier survival curves of anticoagulation status for OS in patients with DD\u0026lt;1.2; (d) Kaplan-Meier survival curves of anticoagulation status for OS in patients with DD≥1.2; (e) Kaplan-Meier survival curves of anticoagulation status for DFS in patients with DD\u0026lt;1.2; (f) Kaplan-Meier survival curves of anticoagulation status for DFS in patients with DD≥1.2.\u003c/p\u003e","description":"","filename":"OnlineFig3.png","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/8179a9aed9745819324f8e5f.png"},{"id":59524275,"identity":"646fded9-45dd-49df-9068-a69a59b98b85","added_by":"auto","created_at":"2024-07-02 20:44:46","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":101379,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot showing results of univariate survival analysis comparing association with overall survival in various subgroups.\u003c/p\u003e","description":"","filename":"Fig41.png","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/bec81d21c73869078b57ecaa.png"},{"id":59524276,"identity":"c47f778e-988c-4bdd-82aa-2ea33caf2837","added_by":"auto","created_at":"2024-07-02 20:44:46","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":100469,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot showing results of univariate survival analysis comparing association with disease-free survival in various subgroups.\u003c/p\u003e","description":"","filename":"Fig51.png","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/cf8a9b4e7a316b48742dbc40.png"},{"id":73942451,"identity":"6705a948-cad6-4eb6-911e-d0b216ab9c0d","added_by":"auto","created_at":"2025-01-16 08:09:36","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1985735,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/ce31a31f-e4f5-4fd0-be77-f7552391b196.pdf"},{"id":59525492,"identity":"d85bcc8e-cd58-4f59-8e10-e8034277ef79","added_by":"auto","created_at":"2024-07-02 20:52:46","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":309410,"visible":true,"origin":"","legend":"","description":"","filename":"Additionalfile1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4550116/v1/4a525e913c684794bdff6ece.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"The effect of low molecular weight heparin on prognosis of patients with radical gastrectomy","fulltext":[{"header":"Introduction","content":"\u003cp\u003eGC remains a major killer worldwide, ranking fifth in incidence and fourth in mortality among malignancies\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e. Radical resection is still the best treatment option for GC under the premise of surgical indications\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e. However, despite significant improvements in surgical technique and perioperative management, the incidence of complications after radical gastrectomy remains high, with an estimated incidence of 12.8\u0026ndash;14%\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003evenous thromboembolism (VTE) is a common complication in patients with cancer. The incidence of first-time VTE in patients with active cancer was 5.8 per 100 person-years. The overall recurrence rate was 9.6 per 100 person-years, with a maximum of 22.1 per 100 person-years in the first 6 months\u003csup\u003e[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/sup\u003e. GC and surgical treatment are both risk factors for VTE and significantly increase mortality. Studies have shown that the incidence of VTE in GC patients after surgery is about 2%, accounting for about 50% of the early postoperative mortality\u003csup\u003e[\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/sup\u003e. Many studies have reported the efficacy of perioperative anticoagulant or antiplatelet drugs in the prevention or treatment of VTE. Although the benefits of LMWH for cancer patient survival are controversial, it appears to be associated with a reduction in VTE, whereas the increase in bleeding is slight and manageable. Recent studies have shown that heparin has anti-cancer effects in addition to its protective effect on the incidence of VTE, such as inhibition of tumor angiogenesis and distant metastases\u003csup\u003e[\u003cspan additionalcitationids=\"CR10\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]\u003c/sup\u003e. However, whether anticoagulant drugs affect the long-term prognosis of patients with GC is unclear\u003csup\u003e[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn this study, we aimed to investigate whether anticoagulation after radical gastrectomy improves the long-term outcomes of patients.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eAssociations between anticoagulation status and clinicopathological factors\u003c/h2\u003e \u003cp\u003eAmong the 1486 patients, 513 (34.52%) received postoperative anticoagulation therapy. No postoperative major bleeding occurred in all patients (data not shown). In the anticoagulation group, prothrombin time (PT) (13 vs 12.9 seconds) and thrombin time (TT) (16.3 vs 16.1 seconds) were higher while albumin (38.1 vs 38.3 g/L), D-dimer (0.4 vs 0.6 mg/L) and fibrin degradation products (FDP) (0.9 vs 1.3 mg/L) were lower. There were no significant differences in age, sex, tumor markers, activated partial prothrombin time (APTT), degree of differentiation, TNM stage and blood routine examination. Most importantly, OS (28 vs 21 months) and DFS (28 vs 20 months) were significantly higher in the anticoagulation group than in the non-anticoagulation group (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDemographic and baseline characteristics of patients.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOverall\u003c/p\u003e \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;1486)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl\u003c/p\u003e \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;973)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnticoagulation\u003c/p\u003e \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;513)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eP value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.931\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1123(75.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e736(75.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e387(75.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e363(24.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e237(24.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e126(24.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge, year\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e61(54\u0026ndash;67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e61(53\u0026ndash;67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e62(57\u0026ndash;69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.235\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin, g/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e38.5(35.5\u0026ndash;41.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38.3(35.2\u0026ndash;41.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38.1(35.38\u0026ndash;39.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.034\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGlobulin, g/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e25.2(22.7\u0026ndash;28)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25(22.58\u0026ndash;27.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e26.79(23.73\u0026ndash;28.68)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.167\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePT, second\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13(12.4\u0026ndash;13.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12.9(12.3\u0026ndash;13.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13(12.3\u0026ndash;13.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAPTT, second\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34.55(32-37.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34.4(32-37.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e36(33-37.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.238\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTT, second\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16.2(15.6\u0026ndash;16.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16.1(15.5\u0026ndash;16.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16.3(15.7\u0026ndash;17.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFibrinogen, g/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.3(2.7\u0026ndash;3.97)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.3(2.71-4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.63(2.97\u0026ndash;4.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.196\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eD-dimer, mg/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.6(0.2\u0026ndash;1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.6(0.2\u0026ndash;1.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.4(0.2\u0026ndash;0.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.009\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFDP, mg/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.2(0.7\u0026ndash;2.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.3(0.7\u0026ndash;2.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9(0.5\u0026ndash;1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.01\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCEA, ng/ml\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.36(1.38\u0026ndash;4.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.44(1.38\u0026ndash;4.92)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.55(1.45\u0026ndash;8.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.33\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA19-9, U/ml\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10.79(6.37\u0026ndash;21.39)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10.75(6.19\u0026ndash;22.07)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.45(5.75\u0026ndash;18.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.772\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA72-4, U/ml\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.04(1.17\u0026ndash;5.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.05(1.17\u0026ndash;5.88)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.89(1.44\u0026ndash;3.65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.42\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOS, month\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24(13\u0026ndash;46)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21(13\u0026ndash;43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e28(12\u0026ndash;69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDFS, month\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24(13\u0026ndash;45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(12\u0026ndash;43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e28(12\u0026ndash;69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDifferentiation\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.96\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e456(30.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e299(30.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e157(30.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1030(69.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e674(69.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e356(69.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e216(14.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e121(12.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e95(18.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e119(8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e80(8.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e39(7.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e301(20.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e237(24.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e64(12.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e850(57.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e535(55)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e315(61.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.027\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e594(40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e375(38.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e219(42.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e282(19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e206(21.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e76(14.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e248(16.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e162(16.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e86(16.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e362(24.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e230(23.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e132(25.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTNM stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.053\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e284(19.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e169(17.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e115(22.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e229(15.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e157(16.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e72(14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e973(65.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e647(66.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e326(63.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTumor size, cm\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4(2.5-6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4(2.5-6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(3\u0026ndash;8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eErythrocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4.26(3.79\u0026ndash;4.64)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.25(3.75\u0026ndash;4.64)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.06(3.7\u0026ndash;4.49)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.393\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemoglobin, g/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e128(108\u0026ndash;142)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e127(106.25\u0026ndash;142)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e123(97-140.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.176\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlatelet\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e201(155-253.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e200(153\u0026ndash;248)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e230(161\u0026ndash;277)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.129\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeukocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.35(4.32\u0026ndash;6.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.28(4.33\u0026ndash;6.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.48(4.28\u0026ndash;6.63)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.898\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeutrophil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.13(2.39\u0026ndash;4.21)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.11(2.38\u0026ndash;4.25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.13(2.19\u0026ndash;4.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.999\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLymphocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.53(1.18\u0026ndash;1.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.53(1.17\u0026ndash;1.94)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.49(1.16\u0026ndash;1.92)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.691\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMonocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.39(0.27\u0026ndash;0.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.4(0.28\u0026ndash;0.52)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.46(0.36\u0026ndash;0.56)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.081\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eAbbreviation: PT prothrombin time, APTT activated partial prothrombin time, TT thrombin time, FDP fibrin degradation products, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19\u0026thinsp;\u0026minus;\u0026thinsp;9, CA72-4 carbohydrate antigen 72\u0026thinsp;\u0026minus;\u0026thinsp;4, OS overall survival, DFS disease free survival, TNM tumor node metastasis.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003csup\u003e#\u003c/sup\u003e Poorly differentiated and undifferentiated were defined as no differentiation, and moderately differentiated and well-differentiated are defined as differentiation.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eResults of survival analysis\u003c/h3\u003e\n\u003cp\u003eContinuous variables were divided into two groups according to their respective suitable cut-off values (Supplementary Fig.\u0026nbsp;1 and Supplementary Fig.\u0026nbsp;2). In univariable analysis, age, anticoagulation status, albumin, globulin, PT, TT, fibrinogen, D-dimer, FDP, CEA, CA19-9, CA72-4, T stage, N stage, TNM stage, tumor size, erythrocyte, hemoglobin, platelet, leukocyte, neutrophil, lymphocyte and monocyte were associated with OS of GC. In multivariable analysis, non-anticoagulation (hazard ratio [HR], 1.397; 95% CI, 1.018\u0026ndash;1.918; P\u0026thinsp;=\u0026thinsp;0.038), higher CEA (HR, 1.792; 95% CI, 1.259\u0026ndash;2.549; P\u0026thinsp;=\u0026thinsp;0.001), higher CA19-9 (HR, 1.719; 95% CI, 1.19\u0026ndash;2.483; P\u0026thinsp;=\u0026thinsp;0.004), advanced N stage (N1: HR, 1.809; 95% CI, 0.988\u0026ndash;3.313; P\u0026thinsp;=\u0026thinsp;0.055; N2: HR, 2.521; 95% CI, 1.375\u0026ndash;4.621; P\u0026thinsp;=\u0026thinsp;0.003; N3: HR, 4.627; 95% CI, 2.63\u0026ndash;8.141; P\u0026thinsp;\u0026lt;\u0026thinsp;0.001), lower erythrocyte (HR, 1.666; 95% CI, 1.16\u0026ndash;2.394; P\u0026thinsp;=\u0026thinsp;0.006) and lower lymphocyte (HR, 1.684; 95% CI, 1.111\u0026ndash;2.553; P\u0026thinsp;=\u0026thinsp;0.014) were independent significant risk factors for OS in GC (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). In univariate analysis of DFS for GC, the relevant factors were the same as those of OS except for monocytes. In multivariate analysis, however, only higher CEA (HR, 1.861; 95% CI, 1.333\u0026ndash;2.579; P\u0026thinsp;\u0026lt;\u0026thinsp;0.001), CA19-9 (HR, 1.53; 95% CI, 1.066\u0026ndash;2.196; P\u0026thinsp;=\u0026thinsp;0.021), advanced N stage (N1: HR, 1.81; 95% CI, 1.039\u0026ndash;3.153; P\u0026thinsp;=\u0026thinsp;0.036; N2: HR, 2.519; 95% CI, 1.439\u0026ndash;4.413; P\u0026thinsp;=\u0026thinsp;0.001; N3: HR, 4.301; 95% CI, 2.545\u0026ndash;7.269; P\u0026thinsp;\u0026lt;\u0026thinsp;0.001), and lower erythrocyte (HR, 1.681; 95% CI, 1.191\u0026ndash;2.372; P\u0026thinsp;=\u0026thinsp;0.003) were identified as independent risk factors for DFS (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eUnivariate and multivariate COX regression analyses for overall survival of GC patients.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eParameters\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eGroup\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c5\" namest=\"c3\"\u003e \u003cp\u003eUnivariate analysis\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003eMultivariate analysis\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e95%CI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eP value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003e95%CI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eP value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale vs male\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.087\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.909\u0026ndash;1.301\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65 vs\u0026thinsp;\u0026ge;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.489\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.272\u0026ndash;1.742\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.273\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.915\u0026ndash;1.771\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.151\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnticoagulant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes vs no\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.551\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.312\u0026ndash;1.833\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.397\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.018\u0026ndash;1.918\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.038\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;32.6 vs\u0026thinsp;\u0026lt;\u0026thinsp;32.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.541\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.987\u0026ndash;3.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.987\u0026ndash;2.531\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.057\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGlobulin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;26.3 vs\u0026thinsp;\u0026ge;\u0026thinsp;26.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.243\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.028\u0026ndash;1.503\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.025\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.963\u0026ndash;1.837\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.083\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;13.2 vs\u0026thinsp;\u0026ge;\u0026thinsp;13.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.114\u0026ndash;1.516\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.148\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.833\u0026ndash;1.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.399\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAPTT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;37.8 vs\u0026thinsp;\u0026ge;\u0026thinsp;37.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.155\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.964\u0026ndash;1.384\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.118\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;16.5 vs\u0026thinsp;\u0026lt;\u0026thinsp;16.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.361\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.141\u0026ndash;1.623\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.977\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.655\u0026ndash;1.458\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.909\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFibrinogen\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;3.7 vs\u0026thinsp;\u0026ge;\u0026thinsp;3.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.751\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.5-2.043\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.003\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.722\u0026ndash;1.394\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.985\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eD-dimer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;1.2 vs\u0026thinsp;\u0026ge;\u0026thinsp;1.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.494\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.111\u0026ndash;2.947\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.276\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.732\u0026ndash;2.222\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.39\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFDP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;3 vs\u0026thinsp;\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.548\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.139\u0026ndash;3.034\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.416\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.806\u0026ndash;2.488\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.226\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCEA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;6.1 vs\u0026thinsp;\u0026ge;\u0026thinsp;6.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.477\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2-3.068\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.792\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.259\u0026ndash;2.549\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA19-9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;35.1 vs\u0026thinsp;\u0026ge;\u0026thinsp;35.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.487\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.939\u0026ndash;3.19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.719\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.19\u0026ndash;2.483\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.004\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA72-4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;2.9 vs\u0026thinsp;\u0026ge;\u0026thinsp;2.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.981\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.595\u0026ndash;2.461\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.142\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.826\u0026ndash;1.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.422\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDifferentiation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes vs no\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.876\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.74\u0026ndash;1.036\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.122\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.833\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.143\u0026ndash;2.94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.012\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.981\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.684\u0026ndash;5.743\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.208\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.009\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.768\u0026ndash;5.805\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3.512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.936\u0026ndash;13.173\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.063\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3.21\u0026ndash;6.335\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3.223\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.889\u0026ndash;11.685\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.075\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.863\u0026ndash;2.966\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.809\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.988\u0026ndash;3.313\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.055\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.826\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.238\u0026ndash;3.568\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.521\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.375\u0026ndash;4.621\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.003\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.115\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3.352\u0026ndash;5.052\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4.627\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e2.63\u0026ndash;8.141\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTNM stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.565\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.748\u0026ndash;3.764\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.715\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.203\u0026ndash;2.516\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.602\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.797\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e4.217\u0026ndash;7.97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.787\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.204\u0026ndash;3.029\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.727\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTumor size\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.157\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.124\u0026ndash;1.191\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.026\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.965\u0026ndash;1.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.412\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eErythrocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;4.5 vs\u0026thinsp;\u0026lt;\u0026thinsp;4.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.837\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.478\u0026ndash;2.282\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.666\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.16\u0026ndash;2.394\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemoglobin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;105 vs\u0026thinsp;\u0026lt;\u0026thinsp;105\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.379\u0026ndash;2.095\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.701\u0026ndash;1.438\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.982\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlatelet\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;136 vs\u0026thinsp;\u0026lt;\u0026thinsp;136\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.051\u0026ndash;1.583\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.015\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.957\u0026ndash;2.352\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.077\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeukocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;8.2 vs\u0026thinsp;\u0026ge;\u0026thinsp;8.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.632\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.233\u0026ndash;2.162\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.594\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.809\u0026ndash;3.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.178\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeutrophil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;5.7 vs\u0026thinsp;\u0026ge;\u0026thinsp;5.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.749\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.329\u0026ndash;2.303\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.692\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.33\u0026ndash;1.449\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.329\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLymphocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;1.1 vs\u0026thinsp;\u0026lt;\u0026thinsp;1.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.973\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.588\u0026ndash;2.452\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.684\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.111\u0026ndash;2.553\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.014\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMonocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.4 vs\u0026thinsp;\u0026ge;\u0026thinsp;0.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.268\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.05\u0026ndash;1.533\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.014\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.967\u0026ndash;1.886\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.078\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"8\"\u003e\u003csup\u003e1\u003c/sup\u003eThe left group served as the control group.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cp\u003eAbbreviation: HR hazard ratio, CI confidence interval, Ref reference, PT prothrombin time, APTT activated partial prothrombin time, TT thrombin time, FDP fibrin degradation products, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, CA72-4 carbohydrate antigen 72-4, TNM tumor node metastasis.\u003c/p\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eUnivariate and multivariate COX regression analyses for disease-free survival of GC patients.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eParameters\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eGroup\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c5\" namest=\"c3\"\u003e \u003cp\u003eUnivariate analysis\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003eMultivariate analysis\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e95%CI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eP value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003e95%CI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eP value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale vs male\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.067\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.895\u0026ndash;1.273\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.467\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65 vs\u0026thinsp;\u0026ge;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.418\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.213\u0026ndash;1.657\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.322\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.962\u0026ndash;1.816\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.086\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnticoagulant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes vs no\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.423\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.21\u0026ndash;1.673\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.305\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.963\u0026ndash;1.768\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.086\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;32.6 vs\u0026thinsp;\u0026lt;\u0026thinsp;32.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.786\u0026ndash;2.937\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.263\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.784\u0026ndash;2.036\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.338\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGlobulin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;26.3 vs\u0026thinsp;\u0026ge;\u0026thinsp;26.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.209\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.004\u0026ndash;1.456\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.045\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.240\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.908\u0026ndash;1.692\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.176\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;13.2 vs\u0026thinsp;\u0026ge;\u0026thinsp;13.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.239\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.064\u0026ndash;1.442\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.006\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.129\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.935\u0026ndash;1.528\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.430\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAPTT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;37.8 vs\u0026thinsp;\u0026ge;\u0026thinsp;37.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.048\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.873\u0026ndash;1.258\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.615\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;16.5 vs\u0026thinsp;\u0026lt;\u0026thinsp;16.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.325\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.111\u0026ndash;1.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.956\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.649\u0026ndash;1.409\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.820\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFibrinogen\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;3.7 vs\u0026thinsp;\u0026ge;\u0026thinsp;3.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.668\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.431\u0026ndash;1.943\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.034\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.753\u0026ndash;1.42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.836\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eD-dimer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;1.2 vs\u0026thinsp;\u0026ge;\u0026thinsp;1.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.918\u0026ndash;2.687\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.217\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.702\u0026ndash;2.109\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.485\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFDP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;3 vs\u0026thinsp;\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.864\u0026ndash;2.667\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.284\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.735\u0026ndash;2.243\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.380\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCEA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;6.1 vs\u0026thinsp;\u0026ge;\u0026thinsp;6.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.352\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.902\u0026ndash;2.908\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.861\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.333\u0026ndash;2.579\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA19-9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;35.1 vs\u0026thinsp;\u0026ge;\u0026thinsp;35.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.276\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.778\u0026ndash;2.914\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.530\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.066\u0026ndash;2.196\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.021\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA72-4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;2.9 vs\u0026thinsp;\u0026ge;\u0026thinsp;2.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.932\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.566\u0026ndash;2.383\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.211\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.888\u0026ndash;1.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.226\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDifferentiation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes vs no\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.874\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.741\u0026ndash;1.032\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.113\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.819\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.166\u0026ndash;2.837\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.008\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.364\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.486\u0026ndash;3.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.555\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.612\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.54\u0026ndash;5.137\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e2.064\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.609\u0026ndash;6.993\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.244\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.148\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3.013\u0026ndash;5.712\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e2.101\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.638\u0026ndash;6.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.222\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.239\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.783\u0026ndash;2.813\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.810\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.039\u0026ndash;3.153\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.036\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.794\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.226\u0026ndash;3.507\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e2.519\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.439\u0026ndash;4.413\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.095\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3.352\u0026ndash;5.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e4.301\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e2.545\u0026ndash;7.269\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTNM stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.367\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.657\u0026ndash;3.381\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.319\u0026ndash;3.284\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.968\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.043\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3.762\u0026ndash;6.761\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.136\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.318\u0026ndash;4.062\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.845\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTumor size\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.158\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.126\u0026ndash;1.191\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.032\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.975\u0026ndash;1.093\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.279\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eErythrocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;4.5 vs\u0026thinsp;\u0026lt;\u0026thinsp;4.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.773\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.436\u0026ndash;2.189\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.681\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e1.191\u0026ndash;2.372\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.003\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemoglobin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;105 vs\u0026thinsp;\u0026lt;\u0026thinsp;105\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.602\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.302\u0026ndash;1.972\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.969\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.682\u0026ndash;1.376\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.860\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlatelet\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;136 vs\u0026thinsp;\u0026lt;\u0026thinsp;136\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.251\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.019\u0026ndash;1.536\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.032\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.516\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.993\u0026ndash;2.314\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.054\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeukocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;8.2 vs\u0026thinsp;\u0026ge;\u0026thinsp;8.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.592\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.205\u0026ndash;2.102\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.350\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.686\u0026ndash;2.655\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.384\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeutrophil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;5.7 vs\u0026thinsp;\u0026ge;\u0026thinsp;5.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.318\u0026ndash;2.271\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.849\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.413\u0026ndash;1.742\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLymphocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;1.1 vs\u0026thinsp;\u0026lt;\u0026thinsp;1.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.465\u0026ndash;2.261\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.387\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.929\u0026ndash;2.071\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.110\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMonocyte\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.4 vs\u0026thinsp;\u0026ge;\u0026thinsp;0.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.172\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.974\u0026ndash;1.41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.093\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"8\"\u003e\u003csup\u003e1\u003c/sup\u003eThe left group served as the control group.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"8\"\u003eAbbreviation: HR hazard ratio, CI confidence interval, Ref reference, PT prothrombin time, APTT activated partial prothrombin time, TT thrombin time, FDP fibrin degradation products, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19\u0026thinsp;\u0026minus;\u0026thinsp;9, CA72-4 carbohydrate antigen 72\u0026thinsp;\u0026minus;\u0026thinsp;4, TNM tumor node metastasis.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eTo explore the prognostic value of anticoagulation in different subgroups, we performed subgroup analyses. Kaplan-Meier curves showed that postoperative anticoagulation was associated with OS regardless of D-dimer level, whereas in the high D-dimer group it was not associated with DFS (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Univariate analysis of OS showed that in the subgroup of female (HR: 2.031 vs 1.431), age\u0026thinsp;\u0026lt;\u0026thinsp;65 years (HR: 1.607 vs 1.501), earlier T (T1 vs T2 vs T3, HR: 3.046 vs 1.93 vs 1.532) and TNM stages (stage I vs stage II vs stage III, HR: 3.305 vs 2.047 vs 1.389), and lower platelet counts (HR: 2.119 vs 1.482), the non-anticoagulant group showed higher HR. Anticoagulation was associated with OS regardless of TNM stage, D-dimer level, FDP level and platelet level (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e). Although postoperative anticoagulation was not an independent risk factor for DFS, we also performed subgroup analyses (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn our current study, we explored the relationship between postoperative anticoagulation and long-term survival in patients undergoing radical gastrectomy for GC. Our results shows that postoperative anticoagulation can significantly improve OS in patients with GC, but there is no significant correlation with DFS. This enlightens us that routine anticoagulation after gastrectomy is necessary.\u003c/p\u003e \u003cp\u003eThrough multivariate survival analysis of anticoagulation status, tumor markers, blood routine, coagulation indexes, and pathological features, we confirmed that anticoagulation can significantly improve OS in patients after radical gastrectomy. Coagulation activation is strongly associated with tumor progression. The improvement of prognosis may be related to the influence of anticoagulant drugs on tumor progression. Pathological activation of the coagulation system occurs in almost all forms of cancer, particularly epithelial malignancies. There is a bidirectional interaction between coagulation activity and cancer, and the activation of the cancer-associated pathological hemostatic system promotes the progression of malignant tumors\u003csup\u003e[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]\u003c/sup\u003e. This was supported by studies showing that men with hemophilia have a lower incidence of prostate cancer\u003csup\u003e[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/sup\u003e. Tissue factors may affect angiogenesis and the pretumorigenic inflammatory environment, thereby supporting tumor development\u003csup\u003e[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u003c/sup\u003e. Microthrombi in the blood protect circulating tumor cells from attack by immune cells\u003csup\u003e[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]\u003c/sup\u003e. In fact, cancer cells can activate the hemostatic system through the release of tissue factors, the expression of procoagulant proteins, the exposure of procoagulant lipids, the release of inflammatory cytokines and microparticles, and the adhesion to host vascular cells\u003csup\u003e[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]\u003c/sup\u003e. Moreover, LMWH downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB\u003csup\u003e[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]\u003c/sup\u003e. This evidence is consistent with our findings. By comparing baseline data, we found that DFS in the anticoagulant group was significantly higher than that in the non-anticoagulant group (median: 28 vs 20 months). Although anticoagulation was not significantly associated with DFS in the multivariate survival analysis, this may be related to our relatively small sample size.\u003c/p\u003e \u003cp\u003eAlthough many studies have reported a close correlation between tumor hypercoagulability and tumor progression, the improvement of OS by postoperative anticoagulant therapy may be related to its effect on cancer-associated thrombosis. Cancer-associated thrombosis, including arterial thrombosis and VTE, significantly affects the quality of life and shortens survival. Although risk assessment tools have been shown to be effective in identifying patients at risk for VTE (including Padua prediction score, Caprini risk assessment model, IMPROVE models, the Geneva risk score and the Kucher score)\u003csup\u003e[\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]\u003c/sup\u003e, and there have been advances in perioperative management and prophylaxis measures, the risk of VTE has increased in recent years. The risk of VTE is related to the type of cancer GC is one of the cancers with the highest risk of VTE as well as individual patient differences and new anticancer therapies including antiangiogenic drugs, multi-targeted tyrosine kinase inhibitors, immunomodulatory drug combinations\u003csup\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]\u003c/sup\u003e. 1-year cumulative risk of pulmonary embolism and deep vein thrombosis for gastroesophageal cancer was 2.3% and 2.19%, respectively. The etiology-specific risk of pulmonary embolism and deep vein thrombosis increased by 10\u0026ndash;30 times in patients undergoing surgery for gastroesophageal cancer, and the post-operative HR gradually decreases until it levels off, but remains higher than that in the general population\u003csup\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/sup\u003e. Therefore, the earlier the use of anticoagulant therapy after surgery, the more effective the prevention of VTE. A large clinical study reported that GC resection exhibited the highest rates of VTE (4.1%). The diagnosis of VTE was associated with increased mortality (10.2% vs 1.7%) and prolonged hospital stay (19.5 days vs 7.5 days), as well as increased rates of readmission and admission costs\u003csup\u003e[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]\u003c/sup\u003e. Therefore, early use of anticoagulant drugs after surgery can effectively reduce VTE events and thus reduce mortality. According to ASCO VTE guideline, patients who are candidates for extended pharmacologic thromboprophylaxis after surgery may be offered prophylactic doses of LMWH (Strength of recommendation: Strong)\u003csup\u003e[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]\u003c/sup\u003e. This may explain our finding that postoperative anticoagulation prolongs OS in patients with GC. Non-anticoagulation was an independent risk factor for the long-term prognosis of GC (HR: 1.397, 95% CI: 1.018\u0026ndash;1.918).\u003c/p\u003e \u003cp\u003eIn addition to the anticoagulant mechanism, heparin also exerts anticancer properties through a non-anticoagulant mechanism\u003csup\u003e[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]\u003c/sup\u003e. Heparin can affect cancer cell proliferation, adhesion, angiogenesis, migration, and invasion through a variety of mechanisms, including inhibition of heparinase, P-/L-selectin, angiogenesis, and interference with the CXCL12-CXCR4 axis\u003csup\u003e[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]\u003c/sup\u003e. Heparin directly induces apoptosis in cancer cells through cell cycle arrest, as well as enhances tumor cell sensitivity to chemotherapy by increasing drug uptake and reversing the downregulation of tumor suppressor genes\u003csup\u003e[\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]\u003c/sup\u003e. Nevertheless, the evidence for the potential survival effect of LMWH is controversial\u003csup\u003e[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/sup\u003e. Moreover, few studies have reported the relationship between LMWH and the prognosis of GC. Our study provides evidence that postoperative anticoagulation prolongs OS in GC.\u003c/p\u003e \u003cp\u003eIt is important to note that perioperative anticoagulation may increase the risk of bleeding. One study showed that patients with esophageal cancer who were treated with anticoagulation in the perioperative period had 22.2% postoperative bleeding incidence, compared with 5.8% in the non-anticoagulation group\u003csup\u003e[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]\u003c/sup\u003e. A clinical study of 1536 patients found that delayed massive hemorrhage after gastrectomy accounted for 0.9%, of which 3 cases died, and early postoperative hemorrhage accounted for 1.2%, and no death cases\u003csup\u003e[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/sup\u003e. A recent study found that preoperative and postoperative use of antithrombotic drugs did not increase bleeding complications after radical gastrectomy\u003csup\u003e[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]\u003c/sup\u003e. Similarly, another study reported that preoperative use of antiplatelet and/or anticoagulants does not significantly increase the risk of major bleeding after laparoscopic GC surgery\u003csup\u003e[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]\u003c/sup\u003e. In our current study, no postoperative major bleeding occurred in the anticoagulant and non-anticoagulant groups, we can conclude that perioperative use of anticoagulant drugs is relatively safe based on the above evidence. The use of anticoagulants needs to meet clinical indications. Individualized treatment with LMWH or oral anticoagulants combined with bleeding risk and VTE risk assessment is critical.\u003c/p\u003e \u003cp\u003eThis study has some limitations in that we did not monitor new postoperative VTE events and the effect of postoperative anticoagulation on VTE risk. The incidence of postoperative major bleeding is relatively low, and a larger sample size may be needed to explore the effect of postoperative anticoagulant drugs on the postoperative bleeding rate.\u003c/p\u003e \u003cp\u003eIn our study we did not investigate the survival difference between prolonged perioperative anticoagulation and postoperative anticoagulation alone. One study reported that prolonged perioperative anticoagulation did not improve DFS or OS in patients with colorectal cancer undergoing surgical resection compared with in-hospital postoperative thromboprophylaxis\u003csup\u003e[\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]\u003c/sup\u003e. The optimal timing of anticoagulation therapy in patients with GC needs to be further explored.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eBased on previous evidence and our findings, we believe that routine anticoagulation with LMWH after radical gastrectomy can improve prognosis without increasing the risk of postoperative bleeding.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePatients\u003c/h2\u003e \u003cp\u003eA total of 1486 GC patients admitted to the The First Affiliated Hospital of Xi'an Jiaotong University between January 2015 and February 2018 were retrospectively enrolled in this study. All patients met the following inclusion criteria: (1) diagnosed with GC for the first time and underwent radical gastrectomy, (2) aged 18+, (3) All patients were assessed for bleeding risk and were at low risk. Exclusion criteria refer to (1) lack of pretreatment coagulation markers, (2) loss to follow-up. Follow-up was conducted by telephone or outpatient clinic. We collected data including age, sex, histological differentiation, tumor markers, coagulation markers, tumor-node-metastasis (TNM) stage and complete blood count from patients before receiving any treatment. Overall survival (OS) was defined as the time interval between the date of first diagnosis and the date of death from any cause or the date of last follow-up. Disease-free survival (DFS) is defined as the time from first diagnosis to postoperative tumor recurrence or metastasis or loss to follow-up. This study was approved by the Ethics Committee of First Affiliated Hospital of Xi\u0026rsquo;an Jiaotong University. Informed consent was obtained from all subjects and/or their legal guardian(s). All methods were performed in accordance with the relevant guidelines and regulations.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analyses\u003c/h2\u003e \u003cp\u003ePostoperative anticoagulation is defined as the use of LMWH for at least one day (such as low molecular weight heparin calcium injection, enoxaparin sodium, or Nagchu heparin calcium). Patients were divided into two groups according to their anticoagulation status and clinicopathological features were compared. Before performing survival analysis, appropriate cut-off values for continuous variables were obtained through \u003cem\u003eX-tile\u003c/em\u003e software (version 3.6.1). The count data was expressed as counts and the frequencies in parentheses and compared by the \u003cem\u003eChi-square\u003c/em\u003e and \u003cem\u003eFisher's exact tests\u003c/em\u003e. Whether the continuous variable follows a normal distribution is tested by the \u003cem\u003eKolmogorov-Smirnov one-sample test\u003c/em\u003e. Normal distribution continuous variables were compared by \u003cem\u003estudent\u0026rsquo;s t-test\u003c/em\u003e, while nonnormal distribution continuous variables were represented as median and interquartile range in parentheses and compared by \u003cem\u003eMann-Whitney U test\u003c/em\u003e. The independent prognostic factors for OS and DFS of GC were determined by Kaplan-Meier curves, univariate and multivariate COX regression analysis. Continuous variables and categorical variables with \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05 in univariate analysis were included in multivariate survival analysis. Subgroup analysis was performed according to age, sex, T stage, N stage, TNM stage, D-dimer level, FDP level and platelet level to evaluate the prognostic value of postoperative anticoagulation. The results of multivariate survival analysis and subgroup analysis were presented by forest plot.\u003c/p\u003e \u003cp\u003eStatistical analysis was performed by SPSS software (version 25.0). \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05 (two-tailed) was considered to be statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eCompeting Interests\u003c/h2\u003e \u003cp\u003eThe authors have no relevant financial or non-financial interests to disclose.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eThe authors declare that no funds, grants, or other support were received during the preparation of this manuscript.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eConceived and designed the experiments: YQW, CXD, DMD, XZ. Performed the experiments: XZ, WXL, JHL. Analyzed the data: XZ, DFW. Contributed reagents/ materials/ analysis tools: XZ, WXL, DFW. Wrote the manuscript: YQW, XZ. All authors reviewed and approved the final manuscript.\u003c/p\u003e\u003ch2\u003eAcknowledgements\u003c/h2\u003e \u003cp\u003eNot applicable.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSung, H. \u003cem\u003eet al\u003c/em\u003e. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians. 71, 209\u0026ndash;249 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIn, H. \u003cem\u003eet al\u003c/em\u003e. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database[J]. Annals of Surgical Oncology. 24, 3683\u0026ndash;3691 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang, S. \u003cem\u003eet al\u003c/em\u003e. Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies[J]. World Journal of Surgical Oncology. 17, (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuo, B. \u003cem\u003eet al\u003c/em\u003e. The ratio of serum C-reactive protein level on postoperative day 3 to day 2 is a good marker to predict postoperative complications after laparoscopic radical gastrectomy for gastric cancer[J]. Langenbecks Arch Surg. 407, 1451\u0026ndash;1460 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCohen, A.T., Katholing, A., Rietbrock, S., Bamber, L. and Martinez, C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study[J]. Thromb Haemost. 117, 57\u0026ndash;65 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKakkar, A., Haas, S., Wolf, H. and Encke, A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy[J]. Thrombosis and haemostasis. 94, 867\u0026ndash;871 (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAgnelli, G. \u003cem\u003eet al\u003c/em\u003e. A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery[J]. Annals of Surgery. 243, 89\u0026ndash;95 (2006).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBj\u0026ouml;rklund, J. \u003cem\u003eet al\u003c/em\u003e. Risk of Venous Thromboembolic Events After Surgery for Cancer[J]. JAMA network open. 7, e2354352 (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGiannas, E. and Kontovounisios, C. The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature[J]. Journal of Clinical Medicine. 12, 7173 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuderer, N.M., Ortel, T.L. and Francis, C.W. Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival[J]. Journal of Clinical Oncology. 27, 4902\u0026ndash;4911 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWei, F. \u003cem\u003eet al\u003c/em\u003e. Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates[J]. Clinical cancer research: an official journal of the American Association for Cancer Research. 29, 2525\u0026ndash;2539 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, N. \u003cem\u003eet al\u003c/em\u003e. Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms[J]. J Cancer Res Clin Oncol. 142, 1807\u0026ndash;1816 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharma, B.K., Flick, M.J. and Palumbo, J.S. Cancer-Associated Thrombosis: A Two-Way Street[J]. Seminars in Thrombosis and Hemostasis. 45, 559\u0026ndash;568 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDunn, A.L., Austin, H. and Soucie, J.M. Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System[J]. Haemophilia. 18, 532\u0026ndash;539 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMilsom, C.C. \u003cem\u003eet al\u003c/em\u003e. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis[J]. Cancer Res. 68, 10068\u0026ndash;10076 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalumbo, J.S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination[J]. Semin Thromb Hemost. 34, 154\u0026ndash;160 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFalanga, A., Panova-Noeva, M. and Russo, L. Procoagulant mechanisms in tumour cells[J]. Best Pract Res Clin Haematol. 22, 49\u0026ndash;60 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDonnellan, E., Kevane, B., Bird, B.R. and Ainle, F.N. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management[J]. Curr Oncol. 21, 134\u0026ndash;143 (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEttelaie, C. \u003cem\u003eet al\u003c/em\u003e. Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-kappaB[J]. Biochim Biophys Acta. 1812, 1591\u0026ndash;1600 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDing, Y. \u003cem\u003eet al\u003c/em\u003e. Risk assessment for postoperative venous thromboembolism using the modified Caprini risk assessment model in lung cancer[J]. Journal of Thoracic Disease. 15, 3386\u0026ndash;3396 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, W., Sun, R., Hu, X., Chen, Z. and Lai, C. Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer[J]. World J Surg Oncol. 21, 299 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDing, Y. \u003cem\u003eet al\u003c/em\u003e. Risk assessment for postoperative venous thromboembolism using the modified Caprini risk assessment model in lung cancer[J]. J Thorac Dis. 15, 3386\u0026ndash;3396 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBar, J. \u003cem\u003eet al\u003c/em\u003e. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study[J]. \u003cem\u003eEuropean journal of cancer (Oxford, England\u003c/em\u003e: 1990). 120, 122\u0026ndash;131 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePan, C.S. \u003cem\u003eet al\u003c/em\u003e. Venous thromboembolism in cancer surgery: A report from the nationwide readmissions database[J]. Surgery Open Science. 9, 58\u0026ndash;63 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKey, N.S. \u003cem\u003eet al\u003c/em\u003e. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update[J]. J Clin Oncol. 41, 3063\u0026ndash;3071 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeurskens, D.M.H. \u003cem\u003eet al\u003c/em\u003e. The Anticoagulant and Nonanticoagulant Properties of Heparin[J]. Thromb Haemost. 120, 1371\u0026ndash;1383 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMa, S.N. \u003cem\u003eet al\u003c/em\u003e. The anti-cancer properties of heparin and its derivatives: a review and prospect[J]. Cell Adh Migr. 14, 118\u0026ndash;128 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen, X., Xiao, W., Qu, X. and Zhou, S. The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro[J]. Cancer Invest. 26, 718\u0026ndash;724 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePan, Y. \u003cem\u003eet al\u003c/em\u003e. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation[J]. Mol Pharmacol. 87, 378\u0026ndash;390 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAoyama, T. \u003cem\u003eet al\u003c/em\u003e. Postoperative Bleeding After Esophagectomy for Esophageal Cancer in Patients Receiving Antiplatelet and Anticoagulation Treatment[J]. Anticancer Research. 40, 2359\u0026ndash;2364 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong, W. \u003cem\u003eet al\u003c/em\u003e. The delayed massive hemorrhage after gastrectomy in patients with gastric cancer: Characteristics, management opinions and risk factors[J]. European Journal of Surgical Oncology (EJSO). 40, 1299\u0026ndash;1306 (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMatsui, R. \u003cem\u003eet al\u003c/em\u003e. Relationship between antithrombotic drugs and postoperative outcomes in patients with gastric cancer after gastrectomy: a propensity matching analysis[J]. Gastric Cancer. 26, 833\u0026ndash;842 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIm, C. \u003cem\u003eet al\u003c/em\u003e. Postoperative major bleeding risk in patients using oral antiplatelets and/or anticoagulants after laparoscopic gastric cancer surgery[J]. Annals of Surgical Treatment and Research. 104, 80 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAuer, R.C. \u003cem\u003eet al\u003c/em\u003e. Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial[J]. BMJ. 378, e071375 (2022).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Gastric cancer, Overall survival, Postoperative anticoagulation, Prognostic factor","lastPublishedDoi":"10.21203/rs.3.rs-4550116/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4550116/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe safety and feasibility of perioperative anticoagulation remains unclear and controversial. In this study, we aim to explored whether postoperative anticoagulation with low molecular weight heparin (LMWH) can improve long-term survival in patients undergoing radical gastrectomy. We retrospectively enrolled 1486 patients diagnosed with primary gastric cancer (GC) and undergoing radical resection in our medical center between January 2015 and February 2018. Patients were grouped into anticoagulation group and non-anticoagulation group based on postoperative anticoagulant therapy, and clinicopathological features were collected and compared. The correlation between parameters and survival was assessed using the Kaplan-Meier method and univariate and multivariate COX regression models. Forest plots were constructed based on subgroup analysis and multivariate Cox regression analysis. Among the 1486 patients, 513 (34.5%) received postoperative anticoagulation therapy. In multivariate survival analysis, non-anticoagulation significantly reduced overall survival (OS), but not disease-free survival (DFS). Furthermore, elevated plasma CEA, CA19-9, lower erythrocyte and lymphocyte counts, and advanced N stage were also shown to be independent poor prognostic factors for OS, and they were also independent prognostic factors for DFS, in addition to lymphocyte counts. Anticoagulation with LMWH after radical gastrectomy can significantly improve the OS of GC patients.\u003c/p\u003e","manuscriptTitle":"The effect of low molecular weight heparin on prognosis of patients with radical gastrectomy","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-02 20:44:41","doi":"10.21203/rs.3.rs-4550116/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d237caf5-ca3d-4440-9005-a48b61397550","owner":[],"postedDate":"July 2nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":33654437,"name":"Health sciences/Gastroenterology/Gastrointestinal diseases/Stomach diseases/Gastric cancer"},{"id":33654438,"name":"Health sciences/Oncology/Surgical oncology"}],"tags":[],"updatedAt":"2025-01-16T08:09:13+00:00","versionOfRecord":[],"versionCreatedAt":"2024-07-02 20:44:41","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4550116","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4550116","identity":"rs-4550116","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}